- Biopharmaceutical company Bionomics (BNO) has initiated trials to test a new tablet form of its post-traumatic stress disorder treatment (PTSD), BNC210
- Then the trial will test the drug’s new solid dose formula after its initial liquid formulation failed to meet efficacy standards in phase two trials
- Findings will then used to determine the dosing regimen of BNC210 for a second phase two clinical trial, expected later this year
- A statement from BNO indicates the study site has prepared and volunteer screenings have commenced
- Results from the study expected in the first quarter of 2021
- BNO shares are up a healthy 3.45 percent on the market
